{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-004254","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.811622+00:00","generated_at":"2026-05-27T01:36:00.832219+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"X4 Pharmaceuticals cuts 30% of workforce, closes Vienna facility, expects $30-35M annual savings","bullets":["Headcount reduced by 43 (~30%); Vienna facility closed; preclinical programs paused.","Estimated $3.0M in severance charges, primarily in Q1 2025.","Annual spending expected to decrease by $30-35M; cash runway into first half 2026.","Phase 3 trial for mavorixafor in chronic neutropenia enrollment on track for mid-2025.","Focus on advancing mavorixafor for chronic neutropenia and optimizing XOLREMDI promotion for WHIM."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-004254","json":"https://secwatch.observer/filing/0001628280-25-004254.json","markdown":"https://secwatch.observer/filing/0001628280-25-004254.md","text":"https://secwatch.observer/filing/0001628280-25-004254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025004254/0001628280-25-004254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025004254/xfor-20250206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:36:00.832219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30ca123346f5983529c0045e905c7780589e54c0","claim":"X4 Pharmaceuticals, Inc announced a restructuring with charges of approximately $3.0 million for severance and other employee termination-related costs affecting the Company (43 employees, or approximately 30% of the Company’s employees).","evidence_excerpt":"The Company estimates that it will incur charges of approximately $3.0 million for severance and other employee termination-related costs, primarily in the first quarter of 2025.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025004254/0001628280-25-004254-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.0 million for severance and other employee termination-related costs"},{"label":"Affected area","value":"the Company"},{"label":"Headcount","value":"43 employees, or approximately 30% of the Company’s employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}